Literature DB >> 20876664

Continual reassessment method with multiple toxicity constraints.

Shing M Lee1, Bin Cheng, Ying Kuen Cheung.   

Abstract

This paper addresses the dose-finding problem in cancer trials in which we are concerned with the gradation of severe toxicities that are considered dose limiting. In order to differentiate the tolerance for different toxicity types and grades, we propose a novel extension of the continual reassessment method that explicitly accounts for multiple toxicity constraints. We apply the proposed methods to redesign a bortezomib trial in lymphoma patients and compare their performance with that of the existing methods. Based on simulations, our proposed methods achieve comparable accuracy in identifying the maximum tolerated dose but have better control of the erroneous allocation and recommendation of an overdose.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20876664      PMCID: PMC3062152          DOI: 10.1093/biostatistics/kxq062

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  12 in total

1.  On the use of nonparametric curves in phase I trials with low toxicity tolerance.

Authors:  Ying Kuen Cheung
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  A simple technique to evaluate model sensitivity in the continual reassessment method.

Authors:  Ying Kuen Cheung; Rick Chappell
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

3.  Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach.

Authors:  Anastasia Ivanova; Se Hee Kim
Journal:  Biometrics       Date:  2008-05-13       Impact factor: 2.571

4.  Stochastic approximation with virtual observations for dose-finding on discrete levels.

Authors:  Ying Kuen Cheung; Mitchell S V Elkind
Journal:  Biometrika       Date:  2009-12-07       Impact factor: 2.445

5.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

6.  A random walk rule for phase I clinical trials.

Authors:  S D Durham; N Flournoy; W F Rosenberger
Journal:  Biometrics       Date:  1997-06       Impact factor: 2.571

7.  Some practical improvements in the continual reassessment method for phase I studies.

Authors:  S N Goodman; M L Zahurak; S Piantadosi
Journal:  Stat Med       Date:  1995-06-15       Impact factor: 2.373

8.  Risk-group-specific dose finding based on an average toxicity score.

Authors:  B Nebiyou Bekele; Yisheng Li; Yuan Ji
Journal:  Biometrics       Date:  2009-07-23       Impact factor: 2.571

9.  The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

Authors:  Z Yuan; R Chappell; H Bailey
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

10.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

View more
  17 in total

1.  Design considerations for dose-expansion cohorts in phase I trials.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J Clin Oncol       Date:  2013-10-07       Impact factor: 44.544

2.  Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2016-11-07       Impact factor: 1.864

3.  Dose-finding designs for cumulative toxicities using multiple constraints.

Authors:  Shing M Lee; Moreno Ursino; Ying Kuen Cheung; Sarah Zohar
Journal:  Biostatistics       Date:  2019-01-01       Impact factor: 5.899

4.  Toxicity burden score: a novel approach to summarize multiple toxic effects.

Authors:  S M Lee; D L Hershman; P Martin; J P Leonard; Y K Cheung
Journal:  Ann Oncol       Date:  2011-05-02       Impact factor: 32.976

5.  Dose-finding designs for trials of molecularly targeted agents and immunotherapies.

Authors:  Cody Chiuzan; Jonathan Shtaynberger; Gulam A Manji; Jimmy K Duong; Gary K Schwartz; Anastasia Ivanova; Shing M Lee
Journal:  J Biopharm Stat       Date:  2017-02-06       Impact factor: 1.051

6.  Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity.

Authors:  Laura L Fernandes; Jeremy M G Taylor; Susan Murray
Journal:  J Biopharm Stat       Date:  2015-06-22       Impact factor: 1.051

7.  Simple benchmark for complex dose finding studies.

Authors:  Ying Kuen Cheung
Journal:  Biometrics       Date:  2014-02-25       Impact factor: 2.571

8.  Multivariate Markov models for the conditional probability of toxicity in phase II trials.

Authors:  Laura L Fernandes; Susan Murray; Jeremy M G Taylor
Journal:  Biom J       Date:  2015-08-07       Impact factor: 2.207

9.  Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.

Authors:  Daniel G Muenz; Thomas M Braun; Jeremy Mg Taylor
Journal:  Clin Trials       Date:  2018-05-19       Impact factor: 2.486

10.  Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.

Authors:  Lingyun Ji; Juan Pablo Lewinger; Mark Krailo; Susan Groshen; David V Conti; Shahab Asgharzadeh; Richard Sposto
Journal:  Pharm Stat       Date:  2019-06-25       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.